MYCN and medulloblastoma: These studies provide evidence for PI3K inhibition with subsequent blockade of MYCN and vascular collapse as a therapeutic strategy across chemical scaffolds and an impetus for the continued development of PI3K inhibitors in MYCN-driven pediatric cancers, including both neuroblastoma and medulloblastoma.